Additional lots of losartan recalled due to potential cancer risk
Sandoz Canada and Sanis Health are recalling all lots of prescription losartan tablets due to the presence of an azido impurity above the acceptable limit. The impurity is a mutagen and can create a heightened cancer risk over time if allowed to rise above certain levels.
The news, announced in a new advisory from Health Canada, marks the latest in a series of recalls of antihypertensive medications in Canada over the last several months. Previous recalls have included losartan, irbesartan and valsartan—all were related to the same azido impurity.
“Continue taking your medication unless you have been advised to stop by your healthcare provider,” Health Canada warned in its advisory. “Not treating your condition may pose a greater health risk.”
Read the full advisory—which includes all updates since the first announcement back in May—here.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.